Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 10, 2008, Pages 3785-3793

  Miller, Paul D ^a   Delmas, Pierre D ^b   Lindsay, Robert ^c   Watts, Nelson B ^d   Luckey, Marjorie ^e   Adachi, Jonathan ^f   Saag, Kenneth ^g   Greenspan, Susan L ^h   Seeman, Ego ⁱ   Boonen, Steven ^j   Meeves, Suzanne ^k   Lang, Thomas F ^l   Bilezikian, John P ^m  

^a University of Colorado Health Sciences Center   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c HELEN HAYES HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Institute of Neurology and Neurosurgery   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g The University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k SANOFI   (France)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Columbia University College of Physicians and Surgeons ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL PROPEPTIDE; COLLAGEN TYPE 1; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DIZZINESS; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 53749105039     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0353     Document Type: Article

References (30)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441
2. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911
3. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
4. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R 2008 Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529-535
5. Ettinger B, San Martin JA, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
6. Neer R, Hayes A, Rao A, Finkelstein J 2002 Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 17(Suppl 1):S135 (Abstract 1039)
7. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM 2006 Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887
8. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
9. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short-term increases in bone turnover marker predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442
10. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
11. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970-3977
12. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
13. Lang TF, Keyak JH, Heitz MW, Augat P, Lu Y, Mathur A, Genant HK 1997 Volumetric quantitative computed tomography of the proximal femur: precision and relation to bone strength. Bone 21:101-108
14. Lang TF, Li J, Harris ST, Genant HK 1999 Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 23:130-137
15. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R 2008 Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623-630
16. dePapp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE 2007 A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222-1230
17. Chen YH, Zhou XH 2006 Interval estimates for the ratio and difference of two lognormal means. Stat Med 25:4099-4113
18. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA 2007 Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149-157
19. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L 2000 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53-56
20. Graeff C, Timm W, Nickelsen TN, Farrerons J, Mar?́n F, Barker C, Glüer CC, EUROFORS High Resolution Computed Tomography Substudy Group 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426-1433
21. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242
22. Fromigué O, Body JJ 2002 Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25:539-546
23. Plotkin LI, Manolagas SC, Bellido T 2006 Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39:443-452
24. Russell RGG, Watts NB, Ebetino FH, Rogers MJ 24 January 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
25. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 617-627
26. Masarachia P, Weinreb M, Balena R, Rodan GA 1996 Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281-290
27. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
28. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365-372
29. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of Teriparatide and alendronate in increasing bone mass. Arch Intern Med [Erratum (2005) 165:2120] 165:1762-1768
30. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370-1375